RE:RE:RE:Lesson from ESPRbear, IMO ESPR at $100 and RVX at $2.75 is perfectly rational, the huge valuation difference is not due to market opportunity (in fact i suspect 208 has a bigger market potential) but here are the salient differences: ESPR leadership A+++++ RVX leadership C-------- (Morris and Wong are bush league compared to ESPR leaders (forget their names)); clinical strategy and execution ESPR A+++++++ RVX D+++++++ (208 is what about 50%), the ASSURE trial was IMO an exhibition of sciience and trial design incompetence (105 (is the the ESPR drug name) has had perfect trial execution., ESPR is overowned by institutions A+++++++, RVX is owned by left coast D------------, so on a DCF price model where RVX is ascribed still 60% chance of failure and ESPR is ascribed 80% of success ESPR is $100 and RVX is $2.50...can Morris and bring in someone with credibility to lead RVX and the price jumps a lot...PS i don't own ESPR but have been looking at it a bit (good candidate for options (puts calls) going into next trial outcome)..but at $0.20 or $0.60 or $1.00 RVX has more upside IMO